Marketing-authorisation holder · United States
Eisai, Incorporated
15 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
15 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
15 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ARICEPT5mg/5ml · Solution | Donepezil | United States | Not marketed | 2004 |
| ARICEPT10mg | 23mg | 5mg · Tablet | Donepezil | United States | Marketed | 1996 |
| ARICEPT ODT10mg | 5mg · Tablet, orally disintegrating | Donepezil | United States | Not marketed | 2004 |
| BANZEL40mg/ml · Suspension | Rufinamide | United States | Marketed | 2011 |
| BANZEL100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200MG | 400MG · Tablet | Rufinamide | United States | Marketed | 2008 |
| DAYVIGO10mg | 5mg · Tablet | Lemborexant | United States | Marketed | 2019 |
| HALAVEN1mg/2ml (0.5mg/ml) · Solution | Eribulin | United States | Marketed | 2010 |
| HEXALEN50mg · Capsule | Altretamine | United States | Not marketed | 1990 |
| LENVIMA10mg base | 4mg base · Capsule | Lenvatinib | United States | Marketed | 2015 |
| LEQEMBI200mg/2ml | 500mg/5ml · Injectable | Lecanemab | United States | Marketed | 2023 |
| Leqembi IQLIK250mg/1.25ml (200mg/ml) · Injection | Lecanemab | United States | Marketed | 2026 |
| Leqembi IQLIK360mg/1.8ml (200mg/ml) · Injection | Lecanemab | United States | Marketed | 2025 |
| LEQEMBI IQLIK360mg/1.8ml(200mg/ml) · Injectable | Lecanemab | United States | Marketed | 2025 |
| LUSEDRA1050mg/30ml (35mg/ml) · Solution | Fospropofol | United States | Not marketed | 2008 |
| ONTAK150ug/ml · Vial | Denileukin diftitox | United States | Marketed | 1999 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 15 | 15 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.